Hospital
Uofl Health-Louisville INC
Uofl Health-Louisville INC was paid $283.15M by Medicaid between Jan 2018 and Dec 2024, across 584 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoUOFL HEALTH-LOUISVILLE INC
LOUISVILLE, KY 40202
LOUISVILLE, KY 40202
33aNPI1639711294assigned 10/15/2019
33bProvider typePsychiatric Hospital
28Total paid$283.15M
24GClaims4,469,131
24DCodes billed584
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital providers in Kentucky
Rank by total paid#1 of 5
Median peer was paid$929K
This provider vs. median305×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 708,258 | $37.79M | |
| 2019 | 676,766 | $39.69M | |
| 2020 | 519,556 | $30.70M | |
| 2021 | 628,329 | $38.85M | |
| 2022 | 666,620 | $45.67M | |
| 2023 | 702,555 | $49.70M | |
| 2024incomplete | 567,047 | $40.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 127,579 | 108,040 | $35.04M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 168,044 | 145,757 | $32.55M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 83,226 | 61,701 | $30.77M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 25,248 | 22,117 | $11.21M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 3.3% | 68,412 | 5,276 | $9.46M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 51,486 | 44,559 | $6.47M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 108,022 | 24,445 | $4.67M |
| 87631 | 1.5% | 37,180 | 34,253 | $4.38M | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 15,919 | 13,912 | $4.37M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 25,561 | 21,826 | $4.20M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.4% | 4,559 | 3,680 | $4.00M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 58,041 | 47,311 | $3.98M |
572 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 102,885 | $3.91M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 9,064 | $3.88M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 86,733 | $3.82M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 86,893 | $3.78M |
| 71045 | Radiologic examination, chest; single view | 1.3% | 66,600 | $3.68M |
| G0378 | Hospital observation service, per hour | 1.3% | 40,165 | $3.58M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 6,311 | $3.42M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.0% | 5,879 | $2.94M |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 1.0% | 29,322 | $2.91M |
| 93458 | <1% | 1,779 | $2.65M | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 56,532 | $2.41M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 8,874 | $2.27M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 28,615 | $2.25M |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 26,529 | $2.14M |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 8,056 | $1.89M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,969 | $1.85M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 45,166 | $1.85M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 26,528 | $1.79M |
| 80053 | Comprehensive metabolic panel | <1% | 189,531 | $1.77M |
| 73630 | <1% | 12,289 | $1.56M | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 838 | $1.56M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,876 | $1.53M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 23,357 | $1.50M |
| C1776 | Joint device (implantable) | <1% | 488 | $1.44M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 38,435 | $1.43M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,728 | $1.37M |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,626 | $1.27M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 47,777 | $1.21M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,165 | $1.18M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 24,065 | $1.14M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 162,603 | $1.10M |
| 73610 | <1% | 10,064 | $1.08M | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,797 | $1.06M |
| 87634 | <1% | 37,183 | $1.03M | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 51,673 | $1.02M |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 23,385 | $1.02M |
| 93017 | <1% | 4,701 | $981K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 28,872 | $951K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,250 | $919K |
| 93971 | <1% | 5,278 | $898K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14,980 | $868K |
| 84484 | <1% | 66,700 | $816K | |
| 73562 | <1% | 6,538 | $814K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,176 | $812K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 14,908 | $812K |
| 73130 | <1% | 10,973 | $773K | |
| 73560 | <1% | 5,972 | $758K | |
| 70486 | <1% | 3,378 | $748K | |
| 83880 | <1% | 24,804 | $734K | |
| 70496 | <1% | 2,357 | $729K | |
| 78264 | <1% | 2,476 | $711K | |
| 70498 | <1% | 2,302 | $710K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,063 | $700K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,844 | $695K |
| 72040 | <1% | 5,639 | $661K | |
| 71250 | <1% | 4,413 | $626K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 165,010 | $612K |
| 96376 | <1% | 13,527 | $596K | |
| 93975 | <1% | 2,587 | $593K | |
| 72131 | <1% | 2,482 | $592K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 69,992 | $592K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 30,100 | $587K |
| 50590 | <1% | 484 | $572K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 7,500 | $556K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 73,139 | $554K |
| 76830 | Ultrasound, transvaginal | <1% | 3,357 | $544K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 21,494 | $528K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 5,147 | $511K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13,156 | $505K |
| 70491 | <1% | 1,690 | $505K | |
| 10060 | <1% | 3,840 | $492K | |
| 84703 | <1% | 67,980 | $479K | |
| 97161 | <1% | 9,952 | $476K | |
| 73030 | <1% | 9,006 | $466K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14,482 | $463K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,122 | $462K |
| 72141 | <1% | 1,228 | $456K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,268 | $454K |
| 72100 | <1% | 10,012 | $451K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 13,322 | $445K |
| J2704 | Injection, propofol, 10 mg | <1% | 34,510 | $437K |
| 73110 | <1% | 6,047 | $428K | |
| C1767 | Generator, neurostimulator (implantable), non-rechargeable | <1% | 74 | $426K |
| 97116 | <1% | 14,504 | $411K | |
| C1781 | Mesh (implantable) | <1% | 1,662 | $405K |
| 47562 | <1% | 271 | $389K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 3,649 | $380K |
| 74018 | <1% | 4,763 | $356K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,226 | $355K |
| 93798 | <1% | 7,282 | $355K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,147 | $344K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 22,873 | $330K |
| 83690 | <1% | 54,227 | $328K | |
| C1820 | Generator, neurostimulator (implantable), with rechargeable battery and charging system | <1% | 78 | $309K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 41,916 | $307K |
| 73080 | <1% | 3,471 | $303K | |
| 85027 | <1% | 52,403 | $300K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 45,760 | $299K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,426 | $296K |
| 76536 | <1% | 1,951 | $295K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,519 | $294K |
| 12001 | <1% | 3,578 | $287K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 119 | $283K |
| 82947 | <1% | 49,345 | $282K | |
| 43235 | <1% | 460 | $281K | |
| 76870 | <1% | 1,588 | $263K | |
| 81001 | <1% | 88,597 | $263K | |
| 93970 | <1% | 1,213 | $257K | |
| 73221 | <1% | 638 | $255K | |
| 88304 | <1% | 4,232 | $254K | |
| 83735 | <1% | 44,015 | $254K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 6,833 | $251K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 32,440 | $248K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,128 | $244K |
| 76770 | <1% | 1,694 | $238K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,384 | $236K |
| C1769 | Guide wire | <1% | 1,851 | $227K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 22,273 | $226K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,804 | $222K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,662 | $222K |
| 82805 | <1% | 3,611 | $221K | |
| 73502 | <1% | 4,871 | $220K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 24,263 | $214K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,747 | $212K |
| 85730 | <1% | 40,714 | $209K | |
| 90715 | <1% | 8,387 | $205K | |
| 85610 | <1% | 52,464 | $205K | |
| 87040 | <1% | 14,700 | $201K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 9,475 | $191K |
| 82553 | <1% | 13,543 | $191K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 27,537 | $187K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,532 | $186K |
| 71101 | <1% | 2,905 | $185K | |
| 80076 | <1% | 23,593 | $185K | |
| 73590 | <1% | 3,403 | $184K | |
| 73700 | <1% | 1,138 | $178K | |
| 73090 | <1% | 3,578 | $177K | |
| 97113 | <1% | 2,659 | $171K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 1,260 | $164K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 10,969 | $160K |
| 83605 | <1% | 15,947 | $157K | |
| 71271 | <1% | 985 | $157K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 15,074 | $156K |
| 43659 | <1% | 112 | $151K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19,518 | $151K |
| 97162 | <1% | 3,488 | $151K | |
| C1874 | Stent, coated/covered, with delivery system | <1% | 150 | $150K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 27,233 | $147K |
| 97032 | <1% | 8,925 | $144K | |
| 92523 | <1% | 1,577 | $143K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15,700 | $138K |
| 87905 | <1% | 11,884 | $137K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 270 | $134K |
| 12002 | <1% | 1,773 | $132K | |
| 64590 | <1% | 245 | $131K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,124 | $128K |
| 29125 | <1% | 2,312 | $128K | |
| 82550 | <1% | 18,198 | $126K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,107 | $125K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 8,480 | $125K |
| 76642 | <1% | 1,234 | $124K | |
| 74183 | <1% | 282 | $124K | |
| 64721 | <1% | 146 | $123K | |
| 87077 | <1% | 14,923 | $123K | |
| 87808 | <1% | 9,423 | $122K | |
| 99218 | <1% | 1,832 | $122K | |
| 76000 | <1% | 2,209 | $122K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,040 | $120K |
| 80061 | Lipid panel | <1% | 11,379 | $120K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 167 | $119K |
| 84702 | <1% | 8,927 | $119K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,190 | $116K |
| 74022 | <1% | 2,111 | $115K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 7,145 | $115K |
| 76801 | <1% | 1,103 | $113K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 227 | $111K |
| 12011 | <1% | 1,662 | $110K | |
| 95806 | <1% | 682 | $108K | |
| 85379 | <1% | 12,103 | $107K | |
| 97165 | <1% | 2,203 | $105K | |
| 73140 | <1% | 2,516 | $105K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 305 | $104K |
| 72070 | <1% | 1,921 | $103K | |
| 93976 | <1% | 537 | $101K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 5,928 | $101K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 5,053 | $101K |
| 93880 | <1% | 594 | $99K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 4,068 | $97K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 9,541 | $97K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 9,902 | $96K |
| 74220 | <1% | 716 | $96K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 7,241 | $96K |
| 29540 | <1% | 1,910 | $94K | |
| 78227 | <1% | 263 | $93K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 3,251 | $92K |
| 77066 | Tomosynthesis, mammo | <1% | 1,076 | $90K |
| 77080 | <1% | 1,881 | $90K | |
| 43770 | <1% | 137 | $88K | |
| 72072 | <1% | 1,151 | $85K | |
| C1762 | Connective tissue, human (includes fascia lata) | <1% | 29 | $83K |
| 80320 | <1% | 2,646 | $82K | |
| 88342 | <1% | 1,213 | $79K | |
| 82565 | <1% | 7,854 | $79K | |
| 87186 | <1% | 9,292 | $78K | |
| 72128 | <1% | 320 | $78K | |
| 87902 | <1% | 318 | $77K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,206 | $77K |
| C1778 | Lead, neurostimulator (implantable) | <1% | 26 | $77K |
| 87081 | <1% | 10,318 | $74K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 7,464 | $73K |
| 99152 | <1% | 2,523 | $72K | |
| 81003 | <1% | 31,640 | $70K | |
| 97166 | <1% | 1,278 | $70K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 8,337 | $69K |
| 73060 | <1% | 1,376 | $69K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 13,109 | $68K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,283 | $68K |
| 97750 | <1% | 1,991 | $68K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 1,622 | $67K |
| 73552 | <1% | 1,243 | $67K | |
| 72082 | <1% | 595 | $67K | |
| 81268 | <1% | 376 | $65K | |
| 96367 | <1% | 1,749 | $65K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,052 | $64K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 6,489 | $64K |
| 86141 | <1% | 5,867 | $62K | |
| 87641 | <1% | 2,262 | $60K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 545 | $60K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 3,701 | $60K |
| 82607 | <1% | 4,555 | $59K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 1,576 | $58K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 43 | $57K |
| 95811 | <1% | 66 | $57K | |
| 93225 | <1% | 488 | $56K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 181 | $56K |
| A9548 | Indium in-111 pentetate, diagnostic, per 0.5 millicurie | <1% | 504 | $55K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 5,074 | $55K |
| 64415 | <1% | 144 | $54K | |
| 88313 | <1% | 1,062 | $54K | |
| 93356 | <1% | 552 | $54K | |
| 10061 | <1% | 345 | $54K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,772 | $53K |
| 74330 | <1% | 345 | $53K | |
| 82728 | <1% | 4,673 | $53K | |
| 88307 | <1% | 395 | $53K | |
| J3490 | Unclassified drugs | <1% | 14,313 | $52K |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 2,125 | $49K |
| 80197 | <1% | 4,771 | $49K | |
| 95980 | <1% | 62 | $47K | |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 907 | $47K |
| 87522 | Neg quan hep c or qual rna | <1% | 1,184 | $47K |
| 94760 | <1% | 6,314 | $46K | |
| 95982 | <1% | 600 | $45K | |
| 87075 | <1% | 5,379 | $43K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 3,723 | $43K |
| 84466 | <1% | 4,028 | $43K | |
| 86850 | <1% | 5,813 | $43K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 456 | $42K |
| 82150 | <1% | 6,334 | $42K | |
| 80329 | <1% | 1,017 | $41K | |
| 84145 | <1% | 2,027 | $40K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 4,626 | $39K |
| 88312 | <1% | 1,332 | $39K | |
| 87070 | <1% | 5,307 | $38K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,549 | $37K |
| 86832 | <1% | 188 | $37K | |
| 96368 | <1% | 910 | $37K | |
| 94060 | <1% | 280 | $37K | |
| 87210 | <1% | 7,372 | $36K | |
| 87149 | <1% | 298 | $36K | |
| J1815 | Injection, insulin, per 5 units | <1% | 10,967 | $36K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 262 | $36K |
| 84100 | <1% | 8,904 | $35K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,823 | $35K |
| 73564 | <1% | 324 | $34K | |
| 97802 | <1% | 1,047 | $34K | |
| 86833 | <1% | 169 | $34K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 2,138 | $33K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,630 | $33K |
| 29505 | <1% | 446 | $32K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 201 | $31K |
| 76641 | <1% | 297 | $30K | |
| 97533 | <1% | 983 | $30K | |
| 97602 | <1% | 534 | $30K | |
| 94726 | <1% | 442 | $30K | |
| 72050 | <1% | 251 | $29K | |
| 87807 | <1% | 2,270 | $29K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,035 | $29K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 245 | $29K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,917 | $28K |
| 84439 | <1% | 3,421 | $28K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 915 | $28K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,109 | $27K |
| 36600 | <1% | 1,147 | $27K | |
| 95981 | <1% | 397 | $26K | |
| 93922 | <1% | 365 | $26K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 104 | $26K |
| 80074 | <1% | 707 | $26K | |
| 83540 | <1% | 4,596 | $25K | |
| 94644 | <1% | 566 | $25K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 50 | $25K |
| 94729 | <1% | 438 | $25K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,664 | $23K |
| 86901 | <1% | 6,874 | $23K | |
| 72170 | <1% | 743 | $22K | |
| 86677 | <1% | 1,373 | $21K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 739 | $21K |
| 83970 | <1% | 425 | $21K | |
| 29515 | <1% | 267 | $20K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,095 | $20K |
| 74178 | <1% | 37 | $20K | |
| 88300 | <1% | 1,135 | $20K | |
| 87205 | <1% | 4,613 | $20K | |
| 93226 | <1% | 229 | $20K | |
| 87088 | <1% | 2,396 | $20K | |
| 87340 | <1% | 2,371 | $20K | |
| 86900 | <1% | 6,849 | $20K | |
| 86038 | <1% | 1,936 | $20K | |
| 82746 | <1% | 1,576 | $19K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 532 | $19K |
| 91132 | <1% | 213 | $19K | |
| 90837 | Psychotherapy session, about an hour | <1% | 924 | $18K |
| 36430 | <1% | 126 | $18K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 10,137 | $18K |
| 82784 | <1% | 934 | $18K | |
| 86803 | <1% | 1,455 | $18K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,960 | $18K |
| 86328 | <1% | 550 | $17K | |
| 29130 | <1% | 324 | $17K | |
| 86140 | <1% | 3,674 | $17K | |
| 29530 | <1% | 587 | $17K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,732 | $17K |
| 43281 | <1% | 24 | $16K | |
| 86704 | <1% | 1,587 | $16K | |
| 84481 | <1% | 1,112 | $15K | |
| 86706 | <1% | 1,592 | $15K | |
| 43236 | <1% | 42 | $15K | |
| 86255 | <1% | 528 | $15K | |
| 81596 | <1% | 313 | $15K | |
| 43274 | <1% | 13 | $15K | |
| 70487 | <1% | 69 | $15K | |
| 82140 | <1% | 1,243 | $15K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 832 | $15K |
| J0878 | Injection, daptomycin, 1 mg | <1% | 74 | $14K |
| 91200 | <1% | 186 | $14K | |
| 84134 | <1% | 885 | $14K | |
| 85652 | <1% | 5,405 | $14K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 122 | $13K |
| 86780 | <1% | 1,289 | $13K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 311 | $13K |
| J0456 | Injection, azithromycin, 500 mg | <1% | 1,241 | $13K |
| 75716 | <1% | 17 | $13K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,968 | $12K |
| 62323 | <1% | 23 | $12K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,776 | $12K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 15 | $12K |
| 96139 | <1% | 31 | $12K | |
| 51702 | <1% | 72 | $12K | |
| 82570 | <1% | 2,651 | $11K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 344 | $11K |
| 77065 | Tomosynthesis, mammo | <1% | 247 | $11K |
| 93350 | <1% | 42 | $11K | |
| 93325 | <1% | 237 | $11K | |
| 83615 | <1% | 2,169 | $11K | |
| 86708 | <1% | 928 | $11K | |
| 75574 | <1% | 58 | $11K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 997 | $11K |
| 86703 | <1% | 927 | $11K | |
| 43253 | <1% | 14 | $11K | |
| 72220 | <1% | 137 | $10K | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 1,335 | $10K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 10,595 | $10K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 116 | $10K |
| 83519 | <1% | 151 | $9K | |
| 84550 | <1% | 2,144 | $8K | |
| 82010 | <1% | 1,096 | $8K | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 604 | $8K |
| 86709 | <1% | 789 | $8K | |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | <1% | 1,138 | $8K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 767 | $8K |
| 83516 | <1% | 478 | $8K | |
| 82105 | <1% | 557 | $8K | |
| 29580 | <1% | 216 | $8K | |
| 88321 | <1% | 211 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 297 | $7K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 50 | $7K |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 293 | $7K |
| 77001 | <1% | 68 | $7K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 605 | $7K |
| 73070 | <1% | 131 | $7K | |
| 83520 | <1% | 514 | $7K | |
| 86308 | <1% | 1,296 | $7K | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 320 | $7K |
| 76882 | <1% | 57 | $7K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 740 | $7K |
| 87428 | <1% | 149 | $7K | |
| 93923 | <1% | 48 | $7K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 37 | $6K |
| G0237 | Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | <1% | 150 | $6K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,201 | $6K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 586 | $6K |
| 64615 | <1% | 30 | $6K | |
| 88341 | <1% | 57 | $6K | |
| 84132 | <1% | 1,686 | $6K | |
| 72146 | <1% | 12 | $6K | |
| 82378 | <1% | 376 | $6K | |
| 84478 | <1% | 1,282 | $5K | |
| 70360 | <1% | 66 | $5K | |
| 84156 | <1% | 1,738 | $5K | |
| 74174 | <1% | 13 | $5K | |
| 93320 | <1% | 63 | $5K | |
| 76857 | <1% | 44 | $5K | |
| 85651 | <1% | 1,547 | $5K | |
| 74170 | <1% | 16 | $5K | |
| 86769 | <1% | 137 | $5K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,946 | $5K |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 736 | $5K |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 61 | $4K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,017 | $4K |
| 97167 | <1% | 79 | $4K | |
| 85049 | <1% | 490 | $4K | |
| 80202 | <1% | 348 | $4K | |
| 64450 | <1% | 21 | $4K | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 552 | $4K |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 72 | $4K |
| 87147 | <1% | 876 | $4K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 414 | $4K |
| 85347 | <1% | 521 | $4K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 1,287 | $4K |
| 82465 | <1% | 1,179 | $4K | |
| 85240 | <1% | 238 | $4K | |
| 70480 | <1% | 12 | $4K | |
| 83550 | <1% | 3,255 | $4K | |
| 80321 | <1% | 2,261 | $4K | |
| 73120 | <1% | 43 | $4K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 24 | $3K |
| 96138 | <1% | 47 | $3K | |
| 92526 | <1% | 63 | $3K | |
| 97127 | <1% | 71 | $3K | |
| 73660 | <1% | 52 | $3K | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 350 | $3K |
| 97542 | <1% | 109 | $3K | |
| 73620 | <1% | 55 | $3K | |
| 87497 | <1% | 74 | $3K | |
| 86480 | <1% | 55 | $3K | |
| 74019 | <1% | 53 | $3K | |
| 85384 | <1% | 341 | $3K | |
| 82172 | <1% | 181 | $3K | |
| 82043 | <1% | 448 | $2K | |
| 97597 | <1% | 20 | $2K | |
| 82542 | <1% | 2,752 | $2K | |
| 93308 | <1% | 18 | $2K | |
| 73200 | <1% | 12 | $2K | |
| 83883 | <1% | 171 | $2K | |
| 29105 | <1% | 41 | $2K | |
| 83010 | <1% | 196 | $2K | |
| 29260 | <1% | 58 | $2K | |
| 99406 | <1% | 120 | $2K | |
| 86705 | <1% | 171 | $2K | |
| 82985 | <1% | 149 | $2K | |
| C1788 | Port, indwelling (implantable) | <1% | 18 | $2K |
| 87341 | <1% | 116 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 172 | $2K |
| 82375 | <1% | 138 | $2K | |
| 76937 | <1% | 44 | $2K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 209 | $2K |
| 84460 | <1% | 353 | $2K | |
| 85018 | <1% | 800 | $2K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 18 | $2K |
| 85014 | <1% | 874 | $2K | |
| 94010 | <1% | 27 | $2K | |
| 94664 | <1% | 73 | $1K | |
| 82977 | <1% | 223 | $1K | |
| 82810 | <1% | 123 | $1K | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 29 | $1K |
| 16020 | <1% | 17 | $1K | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 239 | $1K |
| 87806 | <1% | 45 | $1K | |
| 87140 | <1% | 163 | $1K | |
| 82247 | <1% | 297 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 105 | $1K |
| 82270 | <1% | 296 | $1K | |
| 86920 | <1% | 14 | $1K | |
| 97012 | <1% | 35 | $1K | |
| 82803 | <1% | 68 | $1K | |
| 97760 | <1% | 56 | $1K | |
| 85045 | <1% | 265 | $1K | |
| 82668 | <1% | 51 | $983.52 | |
| 84153 | <1% | 71 | $969.79 | |
| 76942 | <1% | 15 | $961.82 | |
| 85576 | <1% | 46 | $921.73 | |
| 88104 | <1% | 44 | $908.69 | |
| 87799 | <1% | 38 | $904.94 | |
| 80164 | <1% | 80 | $896.05 | |
| 73600 | <1% | 13 | $892.59 | |
| C1883 | Adapter/extension, pacing lead or neurostimulator lead (implantable) | <1% | 12 | $863.08 |
| 71100 | <1% | 26 | $852.04 | |
| 73501 | <1% | 29 | $846.45 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 13 | $841.76 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 541 | $840.65 |
| C1752 | Catheter, hemodialysis/peritoneal, short-term | <1% | 44 | $840.35 |
| 73000 | <1% | 15 | $810.46 | |
| 87536 | <1% | 12 | $790.57 | |
| 86828 | <1% | 15 | $778.61 | |
| 86923 | <1% | 31 | $769.96 | |
| 90686 | <1% | 138 | $751.57 | |
| 12013 | <1% | 13 | $735.27 | |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 58 | $719.52 |
| 82308 | <1% | 36 | $692.84 | |
| 83050 | <1% | 103 | $687.01 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 658 | $666.26 |
| 97164 | <1% | 15 | $665.77 | |
| 87102 | <1% | 58 | $629.99 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 75 | $628.41 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 85 | $613.62 |
| 83789 | <1% | 26 | $608.78 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 37 | $608.77 |
| 97163 | <1% | 13 | $587.32 | |
| A9270 | Non-covered item or service | <1% | 11,507 | $538.00 |
| 82248 | <1% | 123 | $523.72 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 109 | $509.33 |
| 74021 | <1% | 12 | $484.84 | |
| 82379 | <1% | 26 | $481.53 | |
| 82139 | <1% | 89 | $474.31 | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 631 | $467.52 |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 100 | $443.08 |
| 89051 | <1% | 76 | $389.89 | |
| 86849 | <1% | 100 | $389.74 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 47 | $377.38 |
| 86790 | <1% | 29 | $361.39 | |
| 87116 | <1% | 43 | $354.42 | |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 64 | $320.37 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 388 | $308.97 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 47 | $290.64 |
| 84165 | <1% | 31 | $290.37 | |
| 86334 | <1% | 13 | $274.57 | |
| 83090 | <1% | 14 | $273.80 | |
| 83921 | <1% | 14 | $252.05 | |
| 93299 | <1% | 91 | $244.22 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 44 | $239.66 |
| 87449 | <1% | 27 | $220.44 | |
| 87045 | <1% | 38 | $220.34 | |
| 86645 | <1% | 14 | $209.88 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 14 | $199.06 |
| 86644 | <1% | 13 | $197.80 | |
| 84210 | <1% | 13 | $190.55 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 17 | $184.03 |
| 87220 | <1% | 41 | $172.92 | |
| 87206 | <1% | 41 | $165.95 | |
| 84482 | <1% | 12 | $161.25 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 20 | $146.77 |
| 94761 | <1% | 15 | $138.00 | |
| 87015 | <1% | 26 | $130.17 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 17 | $118.98 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 23 | $115.14 |
| 99201 | <1% | 16 | $108.06 | |
| 86593 | <1% | 25 | $104.39 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 576 | $102.71 |
| 84436 | <1% | 12 | $71.39 | |
| 82009 | <1% | 14 | $66.34 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 13 | $60.30 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 175 | $54.19 |
| 86592 | <1% | 12 | $52.93 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 79 | $49.59 |
| 82310 | <1% | 14 | $31.21 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 15 | $16.76 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 270 | $3.46 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | <1% | 17 | $0.53 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 73 | $0.17 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 73 | $0.01 |
| 96119 | 0% | 12 | $0.00 | |
| J0897 | Injection, denosumab, 1 mg | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTRACK, KIRK (CFO)
| Provider | Location | Paid |
|---|---|---|
| University Medical Center, INC | Louisville, KY | $179.41M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.